妊娠早期近期原发性巨细胞病毒感染接受超免疫球蛋白治疗的妊娠结局:观察性研究
这项在德国四家大学医院产前医学科及两家实验室开展的观察性研究纳入149例妊娠(153胎),针对妊娠早期(≤14周)确诊的近期原发性巨细胞病毒感染,自首次给药中位孕10.6周起静脉给予超免疫球蛋白200 IU/kg母体体重、每2周重复至约18周。羊膜腔穿刺时母胎传播率为6.5%(95%CI 3.2-11.7%),抗IgM指数是唯一与传播显著相关的因素。作者认为超免疫球蛋白是预防母胎传播的一种治疗选择,但似乎主要对妊娠早期或围受孕期的近期原发感染、且按200 IU/kg每2周给药者有益。
要点
- 妊娠早期近期原发CMV感染自中位孕10.6周起每2周静脉给予超免疫球蛋白200 IU/kg,羊膜腔穿刺时母胎传播率为6.5%(95%CI 3.2-11.7%)。
- 153胎中143胎(93.5%)未感染,10例(6.5%)发生母胎传播。
- 多因素回归显示抗IgM指数是唯一与羊膜腔穿刺时母胎传播显著相关的因素。
核心结论
- 超免疫球蛋白是预防妊娠期原发性CMV感染母胎传播的一种治疗选择。
- 超免疫球蛋白治疗似乎主要对妊娠早期或围受孕期的近期原发感染、且按200 IU/kg每2周给药者有益。
研究设计与样本
- 正在进行的观察性研究,在德国图宾根、波恩、科隆和埃尔朗根大学医院产前医学科以及斯图加特Gisela Enders教授及同事实验室和图宾根大学医学病毒学研究所开展。
- 纳入标准为妊娠早期确诊的近期原发性CMV感染且首次超免疫球蛋白给药时孕龄≤14周;近期原发感染的判定依据为低抗IgG水平、CMV-IgM阳性时低抗CMV-IgG亲和力且无阳性反应或仅抗gB2-IgG反应血清学转换。
- 共纳入完成治疗的149例妊娠(153胎);母亲中位年龄32.0岁、中位体重65.0kg,首次转诊至四中心之一的中位孕龄9.4周。
- 基线中位抗CMV-IgG水平5.7 U/mL、抗CMV-IgM指数2.5、CMV-IgG亲和力22.3%。
- 超免疫球蛋白于中位孕10.6周开始、中位孕17.9周结束,期间每位患者平均给药4次;羊膜腔穿刺于中位孕20.4周进行。
诊断标准与关键数值
- 主要结局为羊膜腔穿刺时的母胎传播:153胎中10例发生传播,传播率6.5%(95%CI 3.2-11.7%),143例(93.5%)胎儿未感染。
- 单因素和多因素logistic回归分析中,抗IgM指数水平是唯一与羊膜腔穿刺时母胎传播显著相关的因素。
- 10例母胎传播病例中仅4例(40.0%)抗IgM指数高于11.4,该值对应无传播妊娠的第95百分位。
临床应用与阅片要点
- 作者认为超免疫球蛋白是妊娠期原发性CMV感染预防母胎传播的一种治疗选择。
- 作者认为超免疫球蛋白治疗似乎主要对妊娠早期或围受孕期的近期原发感染、且按200 IU/kg每2周给药者有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine the efficacy of hyperimmunoglobulin (HIG) treatment in women with a recent primary cytomegalovirus (CMV) infection up to 14 weeks' gestation.
METHODS: This is an ongoing observational study conducted at the prenatal medicine departments of the University Hospitals of Tübingen, Bonn, Cologne and Erlangen, Germany, as well as at the Laboratory Prof. Gisela Enders and Colleagues in Stuttgart, Germany and the Institute for Medical Virology at the University of Tübingen, Tübingen, Germany. Enrolment criteria were the presence of confirmed recent primary CMV infection in the first trimester and a gestational age at first HIG administration of ≤ 14 weeks. The following inclusion criteria indicated a recent primary infection: low anti-immunoglobulin (Ig)-G levels, low anti-CMV-IgG avidity in the presence of a positive CMV-IgM test and no positive reactivity or just seroconversion anti-gB2-IgG-reactivity. HIG administration was started as soon as possible within a few days after the first visit. HIG was administered intravenously at a dose of 200 IU/kg maternal body weight and repeated every 2 weeks until about 18 weeks' gestation. The primary outcome was maternal-fetal transmission at the time of amniocentesis. Multivariate logistic regression analysis was used to determine significant covariates that could predict maternal-fetal transmission.
RESULTS: We included 149 pregnancies (153 fetuses) that completed the treatment. Median maternal age and weight were 32.0 years and 65.0 kg, respectively. Median gestational age at the time of first referral to one of the four centers was 9.4 weeks. Median anti-CMV-IgG level, anti-CMV-IgM index and CMV-IgG avidity were 5.7 U/mL, 2.5 and 22.3%, respectively. HIG treatment was started at a median gestational age of 10.6 weeks and ended at a median of 17.9 weeks. Within this time frame, HIG was administered on average four times in each patient. Amniocentesis was carried out at a median gestational age of 20.4 weeks. In 143 (93.5%) of the 153 cases, the fetus was not infected. Maternal-fetal transmission occurred in 10 cases (6.5% (95% CI, 3.2-11.7%)). On uni- and multivariate logistic regression analysis, the level of anti-IgM index was the only factor associated significantly with maternal-fetal transmission at amniocentesis. However, only four (40.0%) of the 10 cases with maternal-fetal transmission had an anti-IgM index above 11.4, which corresponds to the 95th centile of pregnancies without transmission.
CONCLUSIONS: HIG is a treatment option to prevent maternal-fetal transmission in pregnancy with a primary CMV infection. However, HIG treatment seems to be beneficial primarily in women with a recent primary infection in the first trimester or during the periconceptional period, and when it is administered at a biweekly dose of 200 IU/kg. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Kagan KO, Enders M, Hoopmann M, et al. Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. Ultrasound Obstet Gynecol. 2021. PMID: 33491819. doi:10.1002/uog.23596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。